Document is current
Any future updates will be listed below
-
Authors
Hammami, M. Bakri https://orcid.org/0000-0003-3422-5163
Knight, Andrew M.
Kherbek, Haidara
Costello, Brian A.
De Lorenzo, Silvana B.
Leibovich, Bradley C.
Cheville, John C.
Guo, Yong
LaFrance-Corey, Reghann G.
Paramasivan, Naveen K. https://orcid.org/0000-0002-2185-4385
Hinson, Shannon R.
Sagen, Jessica
Olson, Janet E. https://orcid.org/0000-0003-4944-7789
Algeciras-Schimnich, Alicia https://orcid.org/0000-0002-4455-6217
Pittock, Sean J.
Mills, John R. https://orcid.org/0000-0003-1025-4760
Dasari, Surendra https://orcid.org/0000-0002-7972-3556
Dubey, Divyanshu https://orcid.org/0000-0001-6865-9045
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (CA210208)
- License Information
-
More Information
Article History
Received: 20 July 2025
Accepted: 10 March 2026
First Online: 1 April 2026
Competing interests
: A.A.S. has participated on advisory boards for Roche Diagnostics and Fujirebio Diagnostics. She has received speaker honoraria from Roche Diagnostics. S.J.P. reports receiving grants, personal fees paid to Mayo Clinic, and nonfinancial support from Alexion Pharmaceuticals, Inc. and MedImmune, Inc./Viela Bio; receiving personal fees from Genentech/Roche, UCB, and Astellas, outside the submitted work; holding patent 8,889,102 (application 12–678350) issued and patent 9,891,219B2 (application 12–573942) issued. D.D. consulted for UCB, Immunovant, Argenx, Arialys, and Astellas Pharmaceuticals. All compensation for consulting activities is paid directly to Mayo Clinic. He is a named inventor on a filed patent that relates to KLHL11 as a marker of autoimmunity and germ cell tumors. He has patents pending for LUZP4-IgG, cavin-4-IgG, and SKOR2-IgG as markers of neurological autoimmunity. He has received funding from the DOD (CA210208 and PR220430), David J. Tomassoni ALS Research Grant Program, and UCB. The rest of the authors have no competing interests.
